Literature DB >> 21537433

Dipeptidyl peptidase-4 inhibitor for steroid-induced diabetes.

Hidekatsu Yanai1, Yoshinori Masui, Reo Yoshikawa, Junwa Kunimatsu, Hiroshi Kaneko.   

Abstract

The addition of the dipeptidyl peptidase-4 (DDP-4) inhibitor has been reported to achieve greater improvements in glucose metabolism with fewer adverse events compared to increasing the metformin dose in type 2 diabetic patients. We present a patient with steroid-induced diabetes whose blood glucose levels were ameliorated by the use of the DPP-4 inhibitor, showing that the DPP-4 inhibitors may be an effective and safe oral anti-diabetic drug for steroid-induced diabetes.

Entities:  

Keywords:  Dipeptidyl peptidase-4; Nateglinide; Sitagliptin; Steroid-induced diabetes

Year:  2010        PMID: 21537433      PMCID: PMC3083887          DOI: 10.4239/wjd.v1.i3.99

Source DB:  PubMed          Journal:  World J Diabetes        ISSN: 1948-9358


  7 in total

1.  Treatment for steroid-induced diabetes with alpha-glucosidase inhibitor, voglibose.

Authors: 
Journal:  Eur J Neurol       Date:  1998-05       Impact factor: 6.089

2.  Effect of vildagliptin as add-on therapy to a low-dose metformin.

Authors:  Claudia Filozof; Sherwyn Schwartz; James E Foley
Journal:  World J Diabetes       Date:  2010-03-15

3.  Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

Authors:  M A Nauck; G Meininger; D Sheng; L Terranella; P P Stein
Journal:  Diabetes Obes Metab       Date:  2007-03       Impact factor: 6.577

Review 4.  The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

Authors:  Daniel J Drucker; Michael A Nauck
Journal:  Lancet       Date:  2006-11-11       Impact factor: 79.321

5.  Combination of the dipeptidyl peptidase IV inhibitor LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] with the angiotensin II type 1 receptor antagonist valsartan [N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl]-L-valine] enhances pancreatic islet morphology and function in a mouse model of type 2 diabetes.

Authors:  Qianni Cheng; Pui Ki Law; Marc de Gasparo; Po Sing Leung
Journal:  J Pharmacol Exp Ther       Date:  2008-09-11       Impact factor: 4.030

6.  Steroid-induced diabetes mellitus and related risk factors in patients with neurologic diseases.

Authors:  Takuya Iwamoto; Yoshiyuki Kagawa; Yutaka Naito; Shigeki Kuzuhara; Michio Kojima
Journal:  Pharmacotherapy       Date:  2004-04       Impact factor: 4.705

7.  Effective use of thiazolidinediones for the treatment of glucocorticoid-induced diabetes.

Authors:  Steven M Willi; Adele Kennedy; Bethany P Brant; Penny Wallace; Nikki L Rogers; W Timothy Garvey
Journal:  Diabetes Res Clin Pract       Date:  2002-11       Impact factor: 5.602

  7 in total
  7 in total

1.  Sitagliptin counteracts seasonal fluctuation of glycemic control.

Authors:  Tomohiro Matsuhashi; Motoaki Sano; Keiichi Fukuda; Shun Kohsaka; Yoshihiko Suzuki
Journal:  World J Diabetes       Date:  2012-06-15

2.  Management of Glucocorticoid-Induced Hyperglycemia.

Authors:  Parag Shah; Sanjay Kalra; Yogesh Yadav; Nilakshi Deka; Tejal Lathia; Jubbin Jagan Jacob; Sunil Kumar Kota; Saptrishi Bhattacharya; Sharvil S Gadve; K A V Subramanium; Joe George; Vageesh Iyer; Sujit Chandratreya; Pankaj Kumar Aggrawal; Shailendra Kumar Singh; Ameya Joshi; Chitra Selvan; Gagan Priya; Atul Dhingra; Sambit Das
Journal:  Diabetes Metab Syndr Obes       Date:  2022-05-23       Impact factor: 3.249

3.  Alogliptin improves steroid-induced hyperglycemia in treatment-naïve Japanese patients with chronic kidney disease by decrease of plasma glucagon levels.

Authors:  Naro Ohashi; Naoko Tsuji; Yoshitaka Naito; Takamasa Iwakura; Shinsuke Isobe; Masafumi Ono; Tomoyuki Fujikura; Takayuki Tsuji; Yukitoshi Sakao; Hideo Yasuda; Akihiko Kato; Yoshihide Fujigaki
Journal:  Med Sci Monit       Date:  2014-04-10

4.  Effects of 6-month sitagliptin treatment on metabolic parameters in diabetic patients taking oral glucocorticoids: a retrospective cohort study.

Authors:  Hisayuki Katsuyama; Akahito Sako; Hiroki Adachi; Hidetaka Hamasaki; Hidekatsu Yanai
Journal:  J Clin Med Res       Date:  2015-04-08

Review 5.  Glucocorticoid-Induced Diabetes Mellitus: An Important but Overlooked Problem.

Authors:  Sunghwan Suh; Mi Kyoung Park
Journal:  Endocrinol Metab (Seoul)       Date:  2017-05-29

Review 6.  Diabetes Mellitus Secondary to Cushing's Disease.

Authors:  Mattia Barbot; Filippo Ceccato; Carla Scaroni
Journal:  Front Endocrinol (Lausanne)       Date:  2018-06-05       Impact factor: 5.555

7.  The effect of liraglutide on insulin allergy in a patient with glucocorticoid-induced diabetes and multiple sclerosis.

Authors:  Jiudan Zhang; Ye Chen; Jian Wang; Hong Xia; Yang Zheng
Journal:  Nagoya J Med Sci       Date:  2021-05       Impact factor: 1.131

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.